Cabaletta Bio Stock
Cabaletta Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Steven A. Nichtberger
- Employees
- 156
- Market cap
- $239 M
- IPO
- 25/10/2019
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric…
Cabaletta Bio stock: price history
1D
-9.0%
1W
-26.9%
1M
-43.4%
6M
-59.0%
YTD
-35.6%
1Y
-51.0%
2Y
-69.7%
5Y
-88.5%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about Cabaletta Bio
Analyst assessment of Cabaletta Bio
PRICE TARGET LOW
US$3.00
CONSENSUS
US$16.33
MEDIAN
US$14.00
PRICE TARGET HIGH
US$32.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 01/09/2026
Cabaletta Bio stock metrics
P/E
-0.89
P/B
1.01
EV/EBITDA
-0.22
RETURN ON EQUITY
-24.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.4%
FLOAT SHARES
141,483,978
AVG. DAILY VOLUME (30D)
5,913,513
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -9.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Cabaletta Bio stock
What does Cabaletta Bio do?
Cabaletta Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Steven A. Nichtberger, the company employs around 156 people.
The IPO was on 25/10/2019; the stock trades on NASDAQ under the ticker CABA.
What do analysts say about Cabaletta Bio stock?
12 analysts rate the stock, the consensus is Buy (as of 01/09/2026).
The average price target is US$16.33, ranging from US$3.00 to US$32.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
When does Cabaletta Bio report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Cabaletta Bio pay a dividend?
No, Cabaletta Bio currently does not pay a dividend.
Which stocks are comparable to Cabaletta Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cabaletta Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cabaletta Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.